Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Dr. Bill Sheridan - CMO Charlie Gayer - CCO Dr. Helen Thackray - Chief R&D Officer Conference Call Participants Stacy Ku - Cowen and Company Jon Wolleben - JMP Securities Chris Raymond - Piper Sandler Jessica Fye - JPMorgan Maury Raycroft - Jefferies Gena Wang - Barclays Brian Abrahams - RBC Cap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) D ...

Call Start: 08:30 January 1, 0000 9:24 AM ET BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2022 Earnings Conference Call May 5, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Dr. Bill Sheridan - Chief Medical Officer Charlie Gayer - Chief Commercial Officer Dr. Helen Thackray - Chief R&D Officer Conference Call Participants Ken Cacciatore - Cowen and Company Jon Wolleben - JMP Securiti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...